<DOC>
	<DOCNO>NCT02371330</DOCNO>
	<brief_summary>This prospective longitudinal study evaluate Platelet Function Analyzer-100 ( PFA-100 ) CT-ADPs ( closure time-ADP ) incidence bleed use Neonatal Bleeding Assessment Tool - Neo-BAT preterm neonate &lt; 32 week gestational age birth weight &lt; 1500 gram different degree thrombocytopenia . The investigator hypothesize PFA-100 CT-ADP , global vitro test primary hemostasis , good predictor clinical bleeding neonate platelet count alone . A bleeding risk assessment marker could help physician accurately determine risk/benefit ratio platelet transfusion , guide platelet transfusion decision neonates thrombocytopenia .</brief_summary>
	<brief_title>The Neonatal Hemorrhagic Risk Assessment Thrombocytopenia Study</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>&lt; 32 week gestation birth weight &lt; 1500 gram ; Have confirm moderatetosevere thrombocytopenia , define platelet count &lt; 100x109/L ; Have parent/guardian willing comply protocol provide write informed consent . Are expect survive Attending Neonatologist ; Are think congenital thrombocytopenia platelet dysfunction , base family history clinical presentation ( e.g . associate congenital malformation , platelet morphology ) ; Have major chromosomal anomaly Trisomy 13 , 18 , 21 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Neonate</keyword>
	<keyword>PFA-100</keyword>
	<keyword>Neo-BAT</keyword>
	<keyword>Hemorrhage</keyword>
</DOC>